New insights on Parkinson’s disease genes: the link between mitochondria impairment and neuroinflammation

Journal of Neural Transmission

Volumn 122, Issue 10, 2015, Pages 1409-1419

  Trudler, Dorit ^a   Nash, Yuval ^a   Frenkel, Dan ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Astrocytes; Inflammation; Microglia; PD genes

Indexed keywords

DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; PARKIN; REACTIVE OXYGEN METABOLITE;

ASTROCYTE; CELL FUNCTION; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; FRONTAL CORTEX; GENE MUTATION; GLIA CELL; HUMAN; MICROGLIA; MITOCHONDRIAL MEMBRANE POTENTIAL; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RESPIRATORY CHAIN; REVIEW; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA; T LYMPHOCYTE; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM;

ANIMALS; HUMANS; MITOCHONDRIA; NEUROIMMUNOMODULATION; PARKINSON DISEASE;

EID: 84942988554     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-015-1399-z     Document Type: Review

References (141)

1. Abou-Sleiman PM, Healy DG, Quinn N, Lees AJ, Wood NW (2003) The role of pathogenic DJ-1 mutations in Parkinson’s disease. Ann Neurol 54:283–286. doi:10.1002/ana.10675
2. Abou-Sleiman PM, Muqit MM, Wood NW (2006) Expanding insights of mitochondrial dysfunction in Parkinson’s disease. Nat Rev Neurosci 7:207–219. doi:10.1038/nrn1868
3. Akundi RS et al (2011) Increased mitochondrial calcium sensitivity and abnormal expression of innate immunity genes precede dopaminergic defects in Pink1-deficient mice. PLoS One 6:e16038. doi:10.1371/journal.pone.0016038
4. Alvarez-Erviti L, Couch Y, Richardson J, Cooper JM, Wood MJ (2011) Alpha-synuclein release by neurons activates the inflammatory response in a microglial cell line. Neurosci Res 69:337–342. doi:10.1016/j.neures.2010.12.020
5. Bader V, Ran Zhu X, Lubbert H, Stichel CC (2005) Expression of DJ-1 in the adult mouse CNS. Brain Res 1041:102–111. doi:10.1016/j.brainres.2005.02.006
6. Bandopadhyay R et al (2004) The expression of DJ-1 (PARK7) in normal human CNS and idiopathic Parkinson’s disease. Brain 127:420–430. doi:10.1093/brain/awh054
7. Benveniste EN (1992) Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiol 263:C1–C16
8. Berger Z, Smith KA, Lavoie MJ (2010) Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation. Biochemistry 49:5511–5523. doi:10.1021/bi100157u
9. Biskup S et al (2006) Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60:557–569. doi:10.1002/ana.21019
10. Blackinton J et al (2005) Effects of DJ-1 mutations and polymorphisms on protein stability and subcellular localization. Brain Res Mol Brain Res 134:76–83. doi:10.1016/j.molbrainres.2004.09.004
11. Blesa J, Phani S, Jackson-Lewis V, Przedborski S (2012) Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol 2012:845618. doi:10.1155/2012/845618
12. Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69. doi:10.1038/nrn2038
13. Bonifati V et al (2003) Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299:256–259. doi:10.1126/science.1077209
14. Brochard V et al (2009) Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Investig 119:182–192. doi:10.1172/JCI36470
15. Cabezas R, Avila MF, Torrente D, El-Bachá RS, Morales L, Gonzalez J, Barreto GE (2013) Astrocytes role in Parkinson: a double-edged sword. In: Uday Kishore (ed) Neurodegenerative disease. doi:10.5772/54305
16. Carvey PM, Punati A, Newman MB (2006) Progressive dopamine neuron loss in Parkinson’s disease: the multiple hit hypothesis. Cell Transplant 15:239–250
17. Casarejos MJ, Menendez J, Solano RM, Rodriguez-Navarro JA, Garcia de Yebenes J, Mena MA (2006) Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J Neurochem 97:934–946. doi:10.1111/j.1471-4159.2006.03777.x
18. Castano A, Herrera AJ, Cano J, Machado A (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J Neurochem 70:1584–1592
19. Chen L et al (2005) Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 280:21418–21426. doi:10.1074/jbc.M413955200
20. Chen PC, Vargas MR, Pani AK, Smeyne RJ, Johnson DA, Kan YW, Johnson JA (2009) Nrf2-mediated neuroprotection in the MPTP mouse model of Parkinson’s disease: critical role for the astrocyte. Proc Natl Acad Sci USA 106:2933–2938. doi:10.1073/pnas.0813361106
21. Chinta SJ, Mallajosyula JK, Rane A, Andersen JK (2010) Mitochondrial alpha-synuclein accumulation impairs complex I function in dopaminergic neurons and results in increased mitophagy in vivo. Neurosci Lett 486:235–239. doi:10.1016/j.neulet.2010.09.061
22. Chung JY et al (2013) Elevated TRAF2/6 expression in Parkinson’s disease is caused by the loss of Parkin E3 ligase activity laboratory investigation. J Tech Methods Pathol. doi:10.1038/labinvest.2013.60
23. Conway KA, Harper JD, Lansbury PT Jr (2000) Fibrils formed in vitro from alpha-synuclein and two mutant forms linked to Parkinson’s disease are typical amyloid. Biochemistry 39:2552–2563
24. Cooper O et al (2012) Pharmacological rescue of mitochondrial deficits in iPSC-derived neural cells from patients with familial Parkinson’s disease. Sci Trans Med 4:141-190. doi:10.1126/scitranslmed.3003985
25. Croisier E, Moran LB, Dexter DT, Pearce RK, Graeber MB (2005) Microglial inflammation in the parkinsonian substantia nigra: relationship to alpha-synuclein deposition. J Neuroinflamm 2:14. doi:10.1186/1742-2094-2-14
26. Dagda RK, Cherra SJ 3rd, Kulich SM, Tandon A, Park D, Chu CT (2009) Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. J Biol Chem 284:13843–13855. doi:10.1021/bi991447r
27. Deas E, Plun-Favreau H, Wood NW (2009) PINK1 function in health and disease. EMBO Mol Med 1:152–165. doi:10.1002/emmm.200900024
28. Deng H, Jankovic J, Guo Y, Xie W, Le W (2005) Small interfering RNA targeting the PINK1 induces apoptosis in dopaminergic cells SH-SY5Y. Biochem Biophys Res Commun 337:1133–1138. doi:10.1016/j.bbrc.2005.09.178
29. Dexter DT et al (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389
30. Fahn S, Clarence-Smith KE, Chase TN (1998) Parkinson’s disease: neurodegenerative mechanisms and neuroprotective interventions—report of a workshop. Mov Disord 13:759–767. doi:10.1002/mds.870130502
31. Frank-Cannon TC et al (2008) Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 28:10825–10834. doi:10.1523/JNEUROSCI.3001-08.2008
32. Frohman EM et al (2005) Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. Arch Neurol 62:1519–1530. doi:10.1001/archneur.62.10.1519
33. Gandhi S et al (2006) PINK1 protein in normal human brain and Parkinson’s disease. Brain 129:1720–1731. doi:10.1093/brain/awl114
34. Gandhi S et al (2009) PINK1-associated Parkinson’s disease is caused by neuronal vulnerability to calcium-induced cell death. Mol Cell 33:627–638. doi:10.1016/j.molcel.2009.02.013
35. Gao HM, Kotzbauer PT, Uryu K, Leight S, Trojanowski JQ, Lee VM (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28:7687–7698. doi:10.1523/JNEUROSCI.0143-07.2008
36. Gao HM, Zhang F, Zhou H, Kam W, Wilson B, Hong JS (2011a) Neuroinflammation and alpha-synuclein dysfunction potentiate each other, driving chronic progression of neurodegeneration in a mouse model of Parkinson’s disease. Environ Health Perspect 119:807–814. doi:10.1289/ehp.1003013
37. Gao HM, Zhou H, Zhang F, Wilson BC, Kam W, Hong JS (2011b) HMGB1 acts on microglia Mac1 to mediate chronic neuroinflammation that drives progressive neurodegeneration. J Neurosci 31:1081–1092. doi:10.1523/JNEUROSCI.3732-10.2011
38. Gillardon F, Schmid R, Draheim H (2012) Parkinson’s disease-linked leucine-rich repeat kinase 2(R1441G) mutation increases proinflammatory cytokine release from activated primary microglial cells and resultant neurotoxicity. Neuroscience 208:41–48. doi:10.1016/j.neuroscience.2012.02.001
39. Goldberg MS et al (2003) Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J Biol Chem 278:43628–43635. doi:10.1074/jbc.M308947200
40. Goldberg MS et al (2005) Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 45:489–496. doi:10.1016/j.neuron.2005.01.041
41. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ (2003) Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 100:4078–4083. doi:10.1073/pnas.0737556100
42. Gu XL, Long CX, Sun L, Xie C, Lin X, Cai H (2010) Astrocytic expression of Parkinson’s disease-related A53T alpha-synuclein causes neurodegeneration in mice. Mol Brain 3:12. doi:10.1186/1756-6606-3-12
43. Haelterman NA, Yoon WH, Sandoval H, Jaiswal M, Shulman JM, Bellen HJ (2014) A mitocentric view of Parkinson’s disease. Annu Rev Neurosci 37:137–159. doi:10.1146/annurev-neuro-071013-014317
44. Hakimi M et al (2011) Parkinson’s disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures. J Neural Transm 118:795–808. doi:10.1007/s00702-011-0653-2
45. Hayashi T et al (2009) DJ-1 binds to mitochondrial complex I and maintains its activity. Biochem Biophys Res Commun 390:667–672. doi:10.1016/j.bbrc.2009.10.025
46. Henchcliffe C, Beal MF (2008) Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis Nature clinical practice. Neurology 4:600–609. doi:10.1038/ncpneuro0924
47. Herrera AJ, Castano A, Venero JL, Cano J, Machado A (2000) The single intranigral injection of LPS as a new model for studying the selective effects of inflammatory reactions on dopaminergic system. Neurobiol Dis 7:429–447. doi:10.1006/nbdi.2000.0289
48. Hirsch EC (2000) Glial cells and Parkinson’s disease. J Neurol 247(Suppl 2):II58–II62
49. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson’s disease: a target for neuroprotection? Lancet Neurol 8:382–397. doi:10.1016/S1474-4422(09)70062-6
50. Imai Y, Soda M, Takahashi R (2000) Parkin suppresses unfolded protein stress-induced cell death through its E3 ubiquitin-protein ligase activity. J Biol Chem 275:35661–35664. doi:10.1074/jbc.C000447200
51. Irrcher I et al (2010) Loss of the Parkinson’s disease-linked gene DJ-1 perturbs mitochondrial dynamics. Hum Mol Genet 19:3734–3746. doi:10.1093/hmg/ddq288
52. Jenner P (2003) Oxidative stress in Parkinson’s disease. Ann Neurol 53(Suppl 3):S26–S36. doi:10.1002/ana.10483 (discussion S36–S28)
53. Kamp F et al (2010) Inhibition of mitochondrial fusion by alpha-synuclein is rescued by PINK1, Parkin and DJ-1. EMBO J 29:3571–3589. doi:10.1038/emboj.2010.223
54. Kim RH et al (2005) Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and oxidative stress. Proc Natl Acad Sci USA 102:5215–5220. doi:10.1073/pnas.0501282102
55. Kim B et al (2012) Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One 7:e34693. doi:10.1371/journal.pone.0034693
56. Kim J, Byun JW, Choi I, Kim B, Jeong HK, Jou I, Joe E (2013) PINK1 deficiency enhances inflammatory cytokine release from acutely prepared brain slices. Exp Neurobiol 22:38–44. doi:10.5607/en.2013.22.1.38
57. Kitada T et al (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605–608. doi:10.1038/33416
58. Klegeris A, Giasson BI, Zhang H, Maguire J, Pelech S, McGeer PL (2006) Alpha-synuclein and its disease-causing mutants induce ICAM-1 and IL-6 in human astrocytes and astrocytoma cells. FASEB J 20:2000–2008. doi:10.1096/fj.06-6183com
59. Klein C, Westenberger A (2012) Genetics of Parkinson’s disease. Cold Spring Harb Perspect Med 2:a008888. doi:10.1101/cshperspect.a008888
60. Klein C, Lohmann-Hedrich K, Rogaeva E, Schlossmacher MG, Lang AE (2007) Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 6:652–662. doi:10.1016/S1474-4422(07)70174-6
61. Kohutnicka M, Lewandowska E, Kurkowska-Jastrzebska I, Czlonkowski A, Czlonkowska A (1998) Microglial and astrocytic involvement in a murine model of Parkinson’s disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39:167–180
62. Koutsilieri E, Scheller C, Grunblatt E, Nara K, Li J, Riederer P (2002) Free radicals in Parkinson’s disease. J Neurol 249(Suppl 2):II1–II5. doi:10.1007/s00415-002-1201-7
63. Lagace-Wiens PR, Decorby MR, Baudry PJ, Hoban DJ, Karlowsky JA, Zhanel GG (2008) Differences in antimicrobial susceptibility in Escherichia coli from Canadian intensive care units based on regional and demographic variables. Can J Infect Dis Med Microbiol 19:282–286
64. Lee HJ, Jang SH, Kim H, Yoon JH, Chung KC (2012) PINK1 stimulates interleukin-1beta-mediated inflammatory signaling via the positive regulation of TRAF6 and TAK1. Cell Mol Life Sci 69:3301–3315. doi:10.1007/s00018-012-1004-7
65. L’Episcopo F et al (2011) Reactive astrocytes and Wnt/beta-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. Neurobiol Dis 41:508–527. doi:10.1016/j.nbd.2010.10.023
66. Lesage S, Brice A (2009) Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18:R48–R59. doi:10.1093/hmg/ddp012
67. Lev N, Ickowicz D, Melamed E, Offen D (2008) Oxidative insults induce DJ-1 upregulation and redistribution: implications for neuroprotection. Neurotoxicology 29:397–405. doi:10.1016/j.neuro.2008.01.007
68. Lev N, Ickowicz D, Barhum Y, Melamed E, Offen D (2009) DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS. J Mol Neurosci 38:94–102. doi:10.1007/s12031-008-9138-7
69. Lev N, Barhum Y, Ben-Zur T, Melamed E, Steiner I, Offen D (2013) Knocking out DJ-1 attenuates astrocytes neuroprotection against 6-hydroxydopamine toxicity. J Mol Neurosci. doi:10.1007/s12031-013-9984-9
70. Lin X et al (2009) Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson’s-disease-related mutant alpha-synuclein. Neuron 64:807–827. doi:10.1016/j.neuron.2009.11.006
71. Liu W et al (2009) PINK1 defect causes mitochondrial dysfunction, proteasomal deficit and alpha-synuclein aggregation in cell culture models of Parkinson’s disease. PLoS One 4:e4597. doi:10.1371/journal.pone.0004597
72. Luk KC, Kehm V, Carroll J, Zhang B, O’Brien P, Trojanowski JQ, Lee VM (2012) Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science 338:949–953. doi:10.1126/science.1227157
73. Marongiu R et al (2009) Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson’s disease by disturbing calcium flux. J Neurochem 108:1561–1574. doi:10.1111/j.1471-4159.2009.05932.x
74. Masliah E et al (2011) Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 6:e19338. doi:10.1371/journal.pone.0019338
75. Mastroeni D et al (2009) Microglial responses to dopamine in a cell culture model of Parkinson’s disease. Neurobiol Aging 30:1805–1817. doi:10.1016/j.neurobiolaging.2008.01.001
76. Mayeux R (2003) Epidemiology of neurodegeneration. Annu Rev Neurosci 26:81–104
77. McGeer PL, McGeer EG (2008) Glial reactions in Parkinson’s disease. Mov Disord 23:474–483. doi:10.1002/mds.21751
78. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson’s and Alzheimer’s disease brains. Neurology 38:1285–1291
79. Meulener M et al (2005) Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson’s disease. Curr Biol 15:1572–1577. doi:10.1016/j.cub.2005.07.064
80. Miller DW, Hague SM, Clarimon J, Baptista M, Gwinn-Hardy K, Cookson MR, Singleton AB (2004) Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62:1835–1838
81. Mitsumoto A, Nakagawa Y (2001) DJ-1 is an indicator for endogenous reactive oxygen species elicited by endotoxin. Free Radical Res 35:885–893
82. Moehle MS et al (2012) LRRK2 inhibition attenuates microglial inflammatory responses. J Neurosci 32:1602–1611. doi:10.1523/JNEUROSCI.5601-11.2012
83. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994a) Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147–150
84. Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T (1994b) Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 165:208–210
85. Moriwaki Y, Kim YJ, Ido Y, Misawa H, Kawashima K, Endo S, Takahashi R (2008) L347P PINK1 mutant that fails to bind to Hsp90/Cdc37 chaperones is rapidly degraded in a proteasome-dependent manner. Neurosci Res 61:43–48. doi:10.1016/j.neures.2008.01.006
86. Mortiboys H, Johansen KK, Aasly JO, Bandmann O (2010) Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 75:2017–2020. doi:10.1212/WNL.0b013e3181ff9685
87. Nagakubo D, Taira T, Kitaura H, Ikeda M, Tamai K, Iguchi-Ariga SM, Ariga H (1997) DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 231:509–513. doi:10.1006/bbrc.1997.6132
88. Narendra D, Tanaka A, Suen DF, Youle RJ (2008) Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 183:795–803. doi:10.1083/jcb.200809125
89. Narendra DP et al (2010) PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 8:e1000298. doi:10.1371/journal.pbio.1000298
90. Nuytemans K, Theuns J, Cruts M, Van Broeckhoven C (2010) Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update. Hum Mutat 31:763–780. doi:10.1002/humu.21277
91. Ooe H, Taira T, Iguchi-Ariga SM, Ariga H (2005) Induction of reactive oxygen species by bisphenol A and abrogation of bisphenol A-induced cell injury by DJ-1. Toxicol Sci 88:114–126. doi:10.1093/toxsci/kfi278
92. Orth M, Schapira AH (2002) Mitochondrial involvement in Parkinson’s disease. Neurochem Int 40:533–541
93. Palacino JJ et al (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 279:18614–18622. doi:10.1074/jbc.M401135200
94. Parker WD Jr, Parks JK, Swerdlow RH (2008) Complex I deficiency in Parkinson’s disease frontal cortex. Brain Res 1189:215–218. doi:10.1016/j.brainres.2007.10.061
95. Perry TL, Yong VW (1986) Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67:269–274
96. Poole AC, Thomas RE, Andrews LA, McBride HM, Whitworth AJ, Pallanck LJ (2008) The PINK1/Parkin pathway regulates mitochondrial morphology. Proc Natl Acad Sci USA 105:1638–1643. doi:10.1073/pnas.0709336105
97. Pridgeon JW, Olzmann JA, Chin LS, Li L (2007) PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biol 5:e172. doi:10.1371/journal.pbio.0050172
98. Reynolds AD et al (2008) Nitrated alpha-synuclein-activated microglial profiling for Parkinson’s disease. J Neurochem 104:1504–1525. doi:10.1111/j.1471-4159.2007.05087.x
99. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer’s disease and Parkinson’s disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82:235–246. doi:10.1016/S0074-7742(07)82012-5
100. Roodveldt C et al (2010) Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: differences between wild-type and Parkinson’s disease-linked mutants. PLoS One 5:e13481. doi:10.1371/journal.pone.0013481
101. Runchel C, Matsuzawa A, Ichijo H (2011) Mitogen-activated protein kinases in mammalian oxidative stress responses. Antioxid Redox Signal 15:205–218. doi:10.1089/ars.2010.3733
102. Saijo K et al (2009) A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons from inflammation-induced death. Cell 137:47–59. doi:10.1016/j.cell.2009.01.038
103. Sanders LH et al (2014) LRRK2 mutations cause mitochondrial DNA damage in iPSC-derived neural cells from Parkinson’s disease patients: reversal by gene correction. Neurobiol Dis 62:381–386. doi:10.1016/j.nbd.2013.10.013
104. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson’s disease. J Neurochem 54:823–827
105. Schapira AH, Gu M, Taanman JW, Tabrizi SJ, Seaton T, Cleeter M, Cooper JM (1998) Mitochondria in the etiology and pathogenesis of Parkinson’s disease. Ann Neurol 44:S89–S98
106. Segev-Amzaleg N, Trudler D, Frenkel D (2013) Preconditioning to mild oxidative stress mediates astroglial neuroprotection in an IL-10-dependent manner. Brain Behav Immun 30:176–185. doi:10.1016/j.bbi.2012.12.016
107. Shavali S, Brown-Borg HM, Ebadi M, Porter J (2008) Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neurosci Lett 439:125–128. doi:10.1016/j.neulet.2008.05.005
108. Sherer TB, Betarbet R, Greenamyre JT (2002) Environment, mitochondria, and Parkinson’s disease. Neuroscientist 8:192–197
109. Sherer TB, Betarbet R, Kim JH, Greenamyre JT (2003) Selective microglial activation in the rat rotenone model of Parkinson’s disease. Neurosci Lett 341:87–90
110. Shimura H et al (2000) Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 25:302–305. doi:10.1038/77060
111. Sidhu A, Wersinger C, Moussa CE, Vernier P (2004) The role of alpha-synuclein in both neuroprotection and neurodegeneration. Ann N Y Acad Sci 1035:250–270. doi:10.1196/annals.1332.016
112. Singleton AB et al (2003) alpha-Synuclein locus triplication causes Parkinson’s disease. Science 302:841. doi:10.1126/science.1090278
113. Singleton AB, Farrer MJ, Bonifati V (2013) The genetics of Parkinson’s disease: progress and therapeutic implications. Mov Disord 28:14–23. doi:10.1002/mds.25249
114. Sofroniew MV (2005) Reactive astrocytes in neural repair and protection. Neuroscientist 11:400–407. doi:10.1177/1073858405278321
115. Spillantini MG, Crowther RA, Jakes R, Hasegawa M (1998) Alpha-synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci USA 95:6469–6473
116. Subramaniam SR, Vergnes L, Franich NR, Reue K, Chesselet MF (2014) Region specific mitochondrial impairment in mice with widespread overexpression of alpha-synuclein. Neurobiol Dis 70:204–213. doi:10.1016/j.nbd.2014.06.017
117. Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H (2004) DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 5:213–218. doi:10.1038/sj.embor.7400074
118. Thevenet J, Pescini Gobert R, Hooft van Huijsduijnen R, Wiessner C, Sagot YJ (2011) Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One 6:e21519. doi:10.1371/journal.pone.0021519
119. Thomas B (2009) Parkinson’s disease: from molecular pathways in disease to therapeutic approaches. Antioxid Redox Signal 11:2077
120. Todd AM, Staveley BE (2008) Pink1 suppresses alpha-synuclein-induced phenotypes in a Drosophila model of Parkinson’s disease. Genome 51:1040–1046. doi:10.1139/G08-085
121. Tran TA, Nguyen AD, Chang J, Goldberg MS, Lee JK, Tansey MG (2011) Lipopolysaccharide and tumor necrosis factor regulate Parkin expression via nuclear factor-kappa B. PLoS One 6:e23660. doi:10.1371/journal.pone.0023660
122. Trudler D, Weinreb O, Mandel SA, Youdim MB, Frenkel D (2014) DJ-1 deficiency triggers microglia sensitivity to dopamine toward a pro-inflammatory phenotype that is attenuated by rasagiline. J Neurochem 129:434–447. doi:10.1111/jnc.12633
123. Vafai SB, Mootha VK (2012) Mitochondrial disorders as windows into an ancient organelle. Nature 491:374–383. doi:10.1038/nature11707
124. Venderova K et al (2009) Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophilamelanogaster model of Parkinson’s disease. Hum Mol Genet 18:4390–4404. doi:10.1093/hmg/ddp394
125. Vives-Bauza C et al (2010) PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci USA 107:378–383. doi:10.1073/pnas.0911187107
126. von Coelln R et al (2006) Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy. J Neurosci Off J Soc Neurosci 26:3685–3696. doi:10.1523/JNEUROSCI.0414-06.2006
127. Waak J et al (2009) Regulation of astrocyte inflammatory responses by the Parkinson’s disease-associated gene DJ-1. FASEB J 23:2478–2489. doi:10.1096/fj.08-125153
128. Wang X et al (2012) LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. Hum Mol Genet 21:1931–1944. doi:10.1093/hmg/dds003
129. Watson MB et al (2012) Regionally-specific microglial activation in young mice over-expressing human wildtype alpha-synuclein. Exp Neurol 237:318–334. doi:10.1016/j.expneurol.2012.06.025
130. Weihofen A, Thomas KJ, Ostaszewski BL, Cookson MR, Selkoe DJ (2009) Pink1 forms a multiprotein complex with Miro and Milton, linking Pink1 function to mitochondrial trafficking. Biochemistry 48:2045–2052. doi:10.1021/bi8019178
131. West AB et al (2005) Parkinson’s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci USA 102:16842–16847. doi:10.1073/pnas.0507360102
132. Wood-Kaczmar A, Gandhi S, Wood NW (2006) Understanding the molecular causes of Parkinson’s disease. Trends Mol Med 12:521–528. doi:10.1016/j.molmed.2006.09.007
133. Xie W, Chung KK (2012) Alpha-synuclein impairs normal dynamics of mitochondria in cell and animal models of Parkinson’s disease. J Neurochem 122:404–414. doi:10.1111/j.1471-4159.2012.07769.x
134. Xiromerisiou G et al (2010) Genetic basis of Parkinson disease. Neurosurg Focus 28:E7. doi:10.3171/2009.10.FOCUS09220
135. Yokota T, Sugawara K, Ito K, Takahashi R, Ariga H, Mizusawa H (2003) Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochem Biophys Res Commun 312:1342–1348
136. Youle RJ, van der Bliek AM (2012) Mitochondrial fission, fusion, and stress. Science 337:1062–1065. doi:10.1126/science.1219855
137. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ (1999) Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154:1423–1429. doi:10.1016/S0002-9440(10)65396-5
138. Zhang L et al (2005a) Mitochondrial localization of the Parkinson’s disease related protein DJ-1: implications for pathogenesis. Hum Mol Genet 14:2063–2073. doi:10.1093/hmg/ddi211
139. Zhang W et al (2005b) Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson’s disease. FASEB J 19:533–542. doi:10.1096/fj.04-2751com
140. Zhang W et al (2007) Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 55:1178–1188. doi:10.1002/glia.20532
141. Zimprich A et al (2004) Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601–607. doi:10.1016/j.neuron.2004.11.005